Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA Caution: Lupin...

    USFDA Caution: Lupin gets OAI letter for MP plant

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-03-17T09:45:23+05:30  |  Updated On 13 Aug 2021 4:35 PM IST

    Lupin has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Mandideep (Unit 1) facility in December 2018 as Official Action Indicated' (OAI), Lupin said in a regulatory filing.


    New Delhi: Drug firm Lupin said Wednesday it has been cautioned by the US health regulator with possible withholding of approvals of pending applications from its Mandideep facility in Madhya Pradesh, where it is facing manufacturing compliance issues.


    The company has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Mandideep (Unit 1) facility in December 2018 as Official Action Indicated' (OAI), Lupin said in a regulatory filing.


    Read Also: Lupin gets USFDA nod for Atorvastatin Calcium tablets to lower cholesterol


    "The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed," it added.


    The Mumbai-based company however clarified that there were no new drug master files (DMF) and Abbreviated New Drug Applications (ANDA) pending review or approval from the Mandideep (Unit 1) facility.


    "The company does not believe that this classification will have an impact on disruption of supplies or the existing revenues from operations of this facility," Lupin said.


    Read Also: Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets


    Lupin is in the process of sending further updates of its corrective actions to the USFDA and remains hopeful of a positive outcome, it added.


    In December last year, the USFDA had issued a total of 22 observations after inspecting the Mandideep facility.

    Read Also: Lupin launches Ranolazine extended release tablets in US
    abbreviated new drug applicationsANDABSEDMFDrug firm Lupindrug master filesLupinLupin PharmaLupin Pharmaceuticalslupin sharesMadhya PradeshMandideep facilityMP plantOAI letterOfficial Action IndicatedUS Food and Drug AdministrationUS healthUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok